R. Huang

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

S. Tu, Lung-Ji Chang, Jilong Yang, 2020, Frontiers in Immunology.

Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis

S. Tu, L. Deng, Chao-Yang Song, 2015, Hematology.

Dendritic cell vaccines extend CAR T‐cell persistence and improve the efficacy of CD19 CAR T‐cell therapy in refractory or relapsed adult B‐ALL patients

S. Tu, Yanjie He, Lijuan Zhou, 2024, American journal of hematology.

Some viral microRNAs were up‐regulated in megakaryocytes incubated with immune thrombocytopenia plasma

Meixia Zhang, Haiyan Hu, Chao-Yang Song, 2013, European journal of haematology.

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

S. Tu, Lung-Ji Chang, Xuan Zhou, 2019, Front. Oncol..

Shortening the ex vivo culture of CD19‐specific CAR T‐cells retains potent efficacy against acute lymphoblastic leukemia without CAR T‐cell‐related encephalopathy syndrome or severe cytokine release syndrome

S. Tu, Lung-Ji Chang, Jilong Yang, 2019, American journal of hematology.

Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML

Shunqing Wang, Yu-Hong Chen, Yu Wang, 2023, American journal of hematology.